Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study.

Wang X, Chen Q, Xu Y, Wang Y, Yang Y, Gu M, Xu H, Zhao Y.

Lipids Health Dis. 2017 Mar 23;16(1):63. doi: 10.1186/s12944-017-0456-z.

2.

Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor.

Measom ND, Down KD, Hirst DJ, Jamieson C, Manas ES, Patel VK, Somers DO.

ACS Med Chem Lett. 2016 Nov 15;8(1):43-48. doi: 10.1021/acsmedchemlett.6b00281. eCollection 2017 Jan 12.

PMID:
28105273
4.

A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.

Qi Y, Zhao D, Jia Z, Wang W, Wang M, Sun J, Liu J, Li Y, Xie W, Liu J.

Sci Rep. 2016 Dec 1;6:37465. doi: 10.1038/srep37465.

6.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.

Rao PP, Kabir SN, Mohamed T.

Pharmaceuticals (Basel). 2010 May 14;3(5):1530-1549. Review.

7.

Lp-PLA2 Inhibition-The Atherosclerosis Panacea?

Karakas M, Koenig W.

Pharmaceuticals (Basel). 2010 Apr 29;3(5):1360-1373. Review.

8.

Development of Accelerated Coronary Atherosclerosis Model Using Low Density Lipoprotein Receptor Knock-Out Swine with Balloon Injury.

Ogita M, Miyauchi K, Onishi A, Tsuboi S, Wada H, Konishi H, Naito R, Dohi T, Kasai T, Kojima Y, Schwartz RS, Daida H.

PLoS One. 2016 Sep 15;11(9):e0163055. doi: 10.1371/journal.pone.0163055. eCollection 2016.

9.

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.

Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER 3rd, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HD; STABILITY Investigators..

J Am Heart Assoc. 2016 Jun 21;5(6). pii: e003407. doi: 10.1161/JAHA.116.003407.

10.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.

Canning P, Kenny BA, Prise V, Glenn J, Sarker MH, Hudson N, Brandt M, Lopez FJ, Gale D, Luthert PJ, Adamson P, Turowski P, Stitt AW.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7213-8. doi: 10.1073/pnas.1514213113. Epub 2016 Jun 13.

11.

Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.

Li X, Fang P, Li Y, Kuo YM, Andrews AJ, Nanayakkara G, Johnson C, Fu H, Shan H, Du F, Hoffman NE, Yu D, Eguchi S, Madesh M, Koch WJ, Sun J, Jiang X, Wang H, Yang X.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1090-100. doi: 10.1161/ATVBAHA.115.306964. Epub 2016 Apr 28.

PMID:
27127201
12.

Replacing carbohydrate with protein and fat in prediabetes or type-2 diabetes: greater effect on metabolites in PBMC than plasma.

Kim M, Song G, Kang M, Yoo HJ, Jeong TS, Lee SH, Lee JH.

Nutr Metab (Lond). 2016 Jan 19;13:3. doi: 10.1186/s12986-016-0063-4. eCollection 2016.

13.

Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Maiolino G, Bisogni V, Rossitto G, Rossi GP.

World J Cardiol. 2015 Oct 26;7(10):609-20. doi: 10.4330/wjc.v7.i10.609. Review.

14.

Göttingen minipig model of diet-induced atherosclerosis: influence of mild streptozotocin-induced diabetes on lesion severity and markers of inflammation evaluated in obese, obese and diabetic, and lean control animals.

Ludvigsen TP, Kirk RK, Christoffersen BØ, Pedersen HD, Martinussen T, Kildegaard J, Heegaard PM, Lykkesfeldt J, Olsen LH.

J Transl Med. 2015 Sep 22;13:312. doi: 10.1186/s12967-015-0670-2.

15.

Inflammation, oxidative stress and renin angiotensin system in atherosclerosis.

Husain K, Hernandez W, Ansari RA, Ferder L.

World J Biol Chem. 2015 Aug 26;6(3):209-17. doi: 10.4331/wjbc.v6.i3.209. Review.

16.

Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.

Lin J, Zheng H, Cucchiara BL, Li J, Zhao X, Liang X, Wang C, Li H, Mullen MT, Johnston SC, Wang Y, Wang Y; CHANCE investigators..

Neurology. 2015 Nov 3;85(18):1585-91. doi: 10.1212/WNL.0000000000001938. Epub 2015 Aug 26.

17.

Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.

He S, Chousterman BG, Fenn A, Anzai A, Nairz M, Brandt M, Hilgendorf I, Sun Y, Ye YX, Iwamoto Y, Tricot B, Weissleder R, Macphee C, Libby P, Nahrendorf M, Swirski FK.

Circ Heart Fail. 2015 Sep;8(5):980-7. doi: 10.1161/CIRCHEARTFAILURE.115.002334. Epub 2015 Jul 31.

18.

The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.

Magee MH, Shaddinger B, Collins D, Siddiqi S, Soffer J.

Br J Clin Pharmacol. 2015 Oct;80(4):654-61. doi: 10.1111/bcp.12661. Epub 2015 Jul 6.

19.

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.

Cai A, Li G, Chen J, Li X, Li L, Zhou Y.

BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.

20.

The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis.

Crawford GL, Boldison J, Copland DA, Adamson P, Gale D, Brandt M, Nicholson LB, Dick AD.

PLoS One. 2015 Apr 15;10(4):e0122093. doi: 10.1371/journal.pone.0122093. eCollection 2015.

Supplemental Content

Support Center